Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
Karyopharm Therapeutics Inc. (the Company) held its 2017 Annual
Meeting of Stockholders on June15, 2017. The following is a
summary of the matters voted on at that meeting.
| 1. |
The Companys stockholders elected J. Scott Garland, Barry E. Greene and Mansoor Raza Mirza, M.D. as class I directors to serve until the 2020 Annual Meeting of Stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders vote with respect to the election of such class I directors were as follows: |
| Votes For | VotesWithheld | BrokerNon-Votes | ||||
|
J. Scott Garland |
31,936,975 | 54,836 | 6,592,242 | |||
|
Barry E. Greene |
31,931,294 | 60,517 | 6,592,242 | |||
|
Mansoor Raza Mirza, M.D. |
31,550,182 | 441,629 | 6,592,242 |
| 2. |
The Companys stockholders ratified the selection of Ernst Young LLP as the Companys independent registered public accounting firm for the current fiscal year. The results of the stockholders vote with respect to such ratification were as follows: |
|
VotesFor |
VotesAgainst |
VotesAbstaining |
||
|
38,563,560 |
19,993 |
About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.